Medical

BLOCKCHAIN ENABLED GENOME SECURITY FROM THE MOMENT IT IS SEQUENCED

June 8, 2022

BLOCK_CHAIN_ENABLED
Sequencing of human genomes is fast becoming an affordable technology for general consumer.

Spotlight

Kadmon Holdings, Inc.

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.

OTHER WHITEPAPERS
news image

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Read More
news image

The colors of life: an interdisciplinary artist-in-residence project to research fungal pigments as a gateway

whitePaper | January 10, 2022

Biological pigmentation is one of the most intriguing traits of many fungi. It holds signifcance to scientists, as a sign of biochemical metabolism and organism-environment interaction, and to artists, as the source of natural colors that capture the beauty of the microbial world.

Read More
news image

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

Read More
news image

A Playbook for Emerging Biotechs

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment

Read More
news image

Could DNA be the next big thing in data storage?

whitePaper | August 19, 2021

DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.

Read More

Spotlight

Kadmon Holdings, Inc.

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.

Events